论文部分内容阅读
【目的】观察趋化性细胞因子CCL18在胰腺癌组织中的表达情况及对患者远期生存率的影响。【方法】本院接受治疗的胰腺癌患者85例，观察其CCL18在胰腺组织中的表达情况，比较CCL18在不同临床病理特征的胰腺癌组织中的阳性表达率，分析CCL18阳性表达率与肿瘤标志物水平的相关性。【结果】死亡组患者CCL18阳性率、肿瘤标志物癌胚抗原（CEA）、糖链抗原199（CA199）、CA125水平明显较生存组高，且差异具有显著性（ P ＜00．5）；年龄较大、分化程度低、有远处转移、侵犯血管的胰腺癌患者CCL18阳性表达率较高，且差异有显著性（ P ＜00．5），而不同性别、肿瘤直径和是否有淋巴结侵犯的患者术后CCL18阳性表达率无明显差异（ P ＞00．5）；胰腺癌患者 CCL18阳性表达率与 CEA ，CA199、CA125等肿瘤标志物指标显著正相关（ P ＜0．05）。【结论】CCL18在预后较差的胰腺癌患者中高表达，且与肿瘤标志物水平正相关，可作为判断患者预后的重要指标。“,”[Objective]To observe the expression of chemokine CCL18 in pancreatic cancer and its effect on the sur‐vival rate of patients with long term .[Methods]The expression of CCL18 in pancreatic tissue of 85 patients with pancreat‐ic cancer who received treatment in our hospital was observed .The positive expression of CCL18 in pancreatic cancer tis‐sue in different clinical and pathological characteristics and the correlation between the positive expression rate of CCL18 and tumor markers were compared and analyzed .[Results]The CCL18 positive rate and tumor markers (CEA ,CA19‐9 and CA125) levels of the death group were significantly higher than those of the survival group;the difference was statis‐tically significant ( P <0 0.5) .Further ,CCL18 positive expression rates were higher in pancreatic cancer patients of older age ,lower differentiation ,distant metastasis ,and invasion of vascular ;the difference had statistical significance ( P <0 0.5) ,while differences of postoperative CCL18 positive expression rates in patients of different genders ,with different tumor sizes ,and with or without lymph node invasion had no significant difference ( P <0 0.5) .Lastly ,the positive ex‐pression rate of CCL18 in patients with pancreatic cancer was significantly positively correlated with CA19‐9 ,CA125 ,and other tumor markers;the difference was statistically significant ( P <0 0.5) .[Conclusion]CCL18 is highly expressed in patients with poor prognosis of pancreatic cancer and is positively correlated with levels of tumor markers ,which can be used as an important indicator in the prognosis of patients with pancreatic cancer .